

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:


Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

On May 5, 2006

MORGAN, LEWIS and BOCKIUS LLP

By: Kathryn Degliant

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE



PATENT
Attorney Docket No.: 61818-5015-US01
Client Reference No.: 2001-433-2

In re application of:

Claude F. Meares, *et al.*

Continuation of Application No.:
10/625,047

Filed: July 22, 2003

For: MULTI-FUNCTIONAL
ANTIBODIES

CUSTOMER NO.: 43850

Confirmation No.: 1090

Examiner: Fetterolf, Brandon J.

Art Unit: 1642

INFORMATION DISCLOSURE
STATEMENT UNDER 37 CFR §1.97 and
§1.98

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

The references cited on attached form PTO/SB/8A are being called to the attention of the Examiner. Copies of the references are enclosed. It is respectfully requested that the cited references be expressly considered during the prosecution of this application, and the references be made of record therein and appear among the "references cited" on any patent to issue therefrom.

As provided for by 37 CFR 1.97(g) and (h), no inference should be made that the information and references cited are prior art merely because they are in this statement and no representation is being made that a search has been conducted or that this statement encompasses all the possible relevant information.

The Commissioner is authorized to deduct the fee for filing an Information Disclosure Statement from the undersigned's Deposit Account No. 50-0310. Please deduct any additional fees from, or credit any overpayment to, the above-noted Deposit Account.

Respectfully submitted,



Todd Esker
Reg. No. 46,690

MORGAN, LEWIS & BOCKIUS, LLP
Two Palo Alto Square
3000 El Camino Real, Ste. 700
Palo Alto, CA 94306
Tel. (415) 442-1000
Direct Dial: (415) 442-1304
eFAX: (650) 843-4001
e-mail: tesker@morganlewis.com
ATTACHMENTS



PTO/SB/08B (08-03)

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet **1** of **2****Complete if Known**

Application Number	10/625,047
Filing Date	July 22, 2003
First Named Inventor	Meares, Claude F.
Art Unit	1642
Examiner Name	Fetterolf, Brandon J.
Attorney Docket Number	61818-5015-US01

NON PATENT LITERATURE DOCUMENTS**U.S. PATENT DOCUMENTS+**

Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number Kind Code ² (if known)			
	AA	US-4,678,667 A	07/07/87	Meares, <i>et al.</i>	
	AB	US-4,722,892 A	02/02/88	Meares, <i>et al.</i>	
	AC	US-5,541,287 A	07/30/96	Yau, <i>et al.</i>	
	AD	US-5,747,654 A	05/05/98	Pastan, <i>et al.</i>	
	AE	US-5,789,554 A	08/04/98	Leung, <i>et al.</i>	
	AF	US-5,837,242 A	11/17/98	Holliger, <i>et al.</i>	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document			Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ²
		Country Code ³	Number ⁴	Kind Code ⁵ (if known)				
	AG	WO	95/15979	A2	06/15/1995			<input type="checkbox"/>

NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	AH	M. Chinol, <i>et al.</i> , "Biodistribution in tumour-bearing mice of two ⁹⁰ Y-labeled biotins using three-step tumour targeting," <u>Nuclear Medicine Comm.</u> , 18:176-182, (1997).	
	AI	David A. Goodwin, <i>et al.</i> , "Pre-targeted immunoscintigraphy: murine tumors with indium-111-labeled bifunctional haptens," <u>J. Nucl. Med.</u> , 29:226-234, (1998).	
	AJ	David A. Goodwin, <i>et al.</i> , "Pretargeted immunoscintigraphy: Effect of hapten valency on murine tumor uptake," <u>J. Nucl. Med.</u> , 33:2006-20013, (1992).	
	AK	D.J. Hnatowich, <i>et al.</i> , "Investigation of avidin and biotin for imaging applications," <u>J. Nucl. Med.</u> , 28:1294-1302, (1987).	
	AL	H.P. Kalofonos, <i>et al.</i> , "Imaging of tumors in patients with indium-111-labeled biotin and streptavidin-conjugated antibodies: Preliminary communication," <u>J. Nucl. Med.</u> , 31:1979-1976, (1990)	
	AM	Alexander L. Klibanov, <i>et al.</i> , "Blood clearance of radiolabeled antibodies: Enhancement by lactosamination and treatment with biotin-avidin or anti-mouse IgG antibodies," <u>J. Nucl. Med.</u> , 29:1951-1956, (1988)	
	AN	J. Ian Marsh, <i>et al.</i> , "Streptavidin and biotin as potential tumor imaging agents," <u>J. Nucl. Med.</u> , 29(05):728-729, (1988)	
	AO	Damon L. Meyer, <i>et al.</i> , "Kinetics of the dissociation of indium-(p-substituted-benzyl)ethylenediaminetetraacetic acid haptens analogues from the monoclonal anti-hapten antibody CHA255," <u>Bioconjugate Chem.</u> , 1:279-284, (1990)	
	AP	Orlandi <i>et al.</i> , <u>Proc. Natl. Acad. Sci.</u> , USA 86:3833-3837, (1989).	
	AQ	Jeffrey T. Owens, <i>et al.</i> , "Mapping the promoter DNA sites proximal to conserved regions of σ^{70} in an <i>escherichia coli</i> RNA polymerase-lacUV5 open promoter complex," <u>Biochemistry</u> , 37:7670-7675, (1998).	

Examiner
Signature

1-SF/7368942.1

Date
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.



Substitute for form 1449B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Application Number	10/625,047
				Filing Date	July 22, 2003
				First Named Inventor	Meares, Claude F.
				Art Unit	1642
				Examiner Name	Fetterolf, Brandon J.
Sheet	1	of	2	Attorney Docket Number	61818-5015-US01

NON PATENT LITERATURE DOCUMENTS

	AR	Jeffrey T. Owens, <i>et al.</i> "Mapping the σ^{70} subunit contact sites on <i>escherichia coli</i> RNA polymerase with a σ^{70} conjugated chemical protease," <u>Proc. Natl. Acad. Sci. USA</u> , 95:6021-6026, (1998)	
	AS	G. Paganelli, <i>et al.</i> , "Three-step monoclonal antibody tumor targeting in carcinoembryonic antigen-positive patients," <u>Cancer Research</u> , 51:5960-5966, (1991)	
	AT	G. Paganelli, <i>et al.</i> , "Monoclonal antibody pretargeting techniques for tumor localization: the avidin-biotin system," <u>Nuclear Medicine Comm.</u> , 12:211-234, (1991).	
	AU	Paul <i>et al.</i> , "Fundamental Immunology Raven Press, NY, Chapter 8: 242, (1993).	
	AV	Dayton T. Reardan, <i>et al.</i> , "Antibodies against metal chelates," <u>Nature</u> , 316:265-268, (1985).	
	AX	Bruno Robert, <i>et al.</i> , "Cytokine targeting in tumors using a bispecific antibody directed against carinoembryonic antigen and tumor necrosis factor α^1 ," <u>Cancer Research</u> , 56:4758-4765, (1996).	
	AY	Eric Rouvier, <i>et al.</i> , "Targeting medullary thyroid carcinomas with bispecific antibodies and bivalent haptens," <u>Horm. Res.</u> , 47:163-167, (1997).	
	AZ	Rudikoff, <i>et al.</i> <u>Proc. Natl. Sci. USA</u> , 79:1979-1983, (1982).	
	BA	B. Schechter, <i>et al.</i> , "Indirect immunotargeting of CIS-PT to human epidermoid carcinoma KB using the avidin-biotin system," <u>Int. J. Cancer</u> , 48:167-172, (1991).	
	BB	Vladimir V. Sinitsyn, <i>et al.</i> , "Rapid blood clearance of biotinylated IgG after infusion of avidin," <u>J. Nucl. Med.</u> , 30:66-69, (1989).	
	BC	Fan Yuna, <i>et al.</i> , "Pharmacokinetic analysis of two step approaches using bifunctional and enzyme-conjugated antibodies," <u>Cancer Research</u> , 51:3119-3130, (1991).	

Examiner Signature	1-SF/7368942.1	Date Considered	
--------------------	----------------	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.